National Graphite Corp. (NGRC)
National Graphite Corp. operates in the Shell Companies industry of the Financial Services sector, headquartered in Las Vegas, NV, US. The stock last traded at $0.02, up 0.00% on the session, giving a market capitalisation of $3.2M. On trailing twelve-month figures it carries a trailing P/E of 52.50, a net margin of 0.0%. Its beta of -1.28 implies it has historically moved less than the broad market.
National Graphite Corp. (NGRC), operating through its subsidiary Biotech Development Corp., functions as a biopharmaceutical enterprise specializing in risk and cost-sharing models. The company establishes partnerships with clinical-stage firms dedicated to developing novel biological entities or innovative therapeutic platforms. These collaborations aim to address a wide spectrum of health conditions, encompassing common illnesses, rare disorders, and those with significant unmet medical requirements. Among its key pipeline developments is ELAFIN, a drug candidate identified as a human-identical protein. ELAFIN is being developed specifically for the management of postoperative inflammatory complications. The advancement of ELAFIN is further supported by a collaboration agreement with Proteo Inc. Founded in 2006, National Graphite Corp. was formerly known as Lucky Boy Silver Corporation until it officially adopted its current name in May 2012. The company maintains its operational headquarters in Duesseldorf, Germany.
National Graphite Corp. is most often compared with the following Financial Services names: